Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

Gross Margin · Q3 FY2026 · quarter ended Sep 2026

Gross margin narrows to -232.1%

Gross margin was -232.1% in Q3 FY2026, down 311.3 pp from a year earlier. On a trailing-twelve-month basis it was 0.5%, down 88.3 pp year over year. Over 3 fiscal years it narrowed by 3.1 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-232.1%-325.1 pp QoQ
Last fiscal yearDec 2025
93.2%+0.2 pp YoY
LTMSep 2026
0.5%-88.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-311.3 pp——
1 year+0.2 pp——
3 years-3.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.2%
Year-over-year change
+0.2pp

Gross Margin vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's LTM Sep 2026 gross margin of 0.5% is the lowest of the 5 companies compared; the peer median is 90.3%.
  • Its year-over-year change of -88.3 pp is the lowest of 5, against a peer median of +9.9 pp.
  • Over three fiscal years its change of -3.1 pp compares with a peer median of +7.2 pp.
TARS Competitors Peer median
Gross Margin for TARS and competitors
Company Period LTM level YoY 3-year change
SLGLSol-Gel Technologies Ltd.LTM Mar 2026100.0% +20.1 pp+326.6 pp
ARQTArcutis Biotherapeutics, Inc.LTM Jun 202691.1% +2.0 pp+10.7 pp
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202689.5% +17.7 pp-1.6 pp
HROWHarrow Health, Inc.LTM Mar 202674.1% -0.4 pp+3.7 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 20260.5% -88.3 pp-3.1 pp
TTRXTurn Therapeutics Inc.FY2025— ——
Peer median (excluding TARS) 90.3%+9.9 pp+7.2 pp

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue57.03M25.82M17.45M182.95M451.36M
Cost of Revenue2.08M955K1.59M12.83M30.68M
Gross Profit54.95M24.86M15.85M170.13M420.68M
Gross Margin96.4%96.3%90.9%93.0%93.2%
Research & Development41.71M42.62M50.31M53.39M64.32M
Selling, General & Admin25.4M44.95M108.7M237.31M427.32M
Operating Expenses67.11M87.57M159.01M290.7M491.65M
Depreciation & Amortization312K326K877K1.23M1.82M
EBITDA(13.46M)(59.71M)(131.67M)(106.48M)(53.61M)
EBITDA Margin-23.6%-231.3%-754.7%-58.2%-11.9%
Operating Income(12.16M)(62.71M)(143.16M)(120.57M)(70.97M)
Operating Margin-21.3%-242.9%-820.5%-65.9%-15.7%
Interest Income36K3.5M10.34M15.01M15.75M
Interest Expense02.06M3.23M7.45M8.94M
Other Income / Expenses(1.62M)617K7.27M5.02M6.61M
Income Before Tax(13.77M)(62.1M)(135.89M)(115.55M)(64.36M)
Pre-Tax Margin-24.1%-240.5%-778.9%-63.2%-14.3%
Income Tax Expense55K(4K)002.06M
Net Income(13.83M)(62.09M)(135.89M)(115.55M)(66.42M)
Net Margin-24.2%-240.5%-778.9%-63.2%-14.7%
EPS (Basic)(0.67)(2.52)(4.62)(3.07)(1.59)
EPS (Diluted)(0.67)(2.52)(4.62)(3.07)(1.59)
Weighted Avg Shares20.55M24.62M29.38M37.6M41.78M
Weighted Avg Shares (Diluted)20.55M24.62M29.38M37.6M41.78M

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.